A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2

Xiaolei Cai,1 Aleksander Prominski,2 Yiliang Lin,2 Nicholas Ankenbruck,1 Jillian Rosenberg,3 Min Chen,1 Jiuyun Shi,2 Eugene B. Chang,4 Pablo Penaloza-MacMaster,5 Bozhi Tian,2 and Jun Huang*1

1Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA
2Department of Chemistry, University of Chicago, Chicago, IL 60637, USA
3Committee on Cancer Biology, University of Chicago, Chicago, IL 60637, USA
4Department of Medicine, University of Chicago, Chicago, IL 60637, USA
5Department of Microbiology-Immunology, Northwestern University, Chicago, IL 60611

*Corresponding author: huangjun@uchicago.edu

Keywords: COVID-19, SARS-CoV-2, photothermal nanoparticle, photothermal therapy, virus inactivation
ABSTRACT

The outbreak of 2019 coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic. Despite intensive research including several clinical trials, currently there are no completely safe or effective therapeutics to cure the disease. Here we report a strategy incorporating neutralizing antibodies conjugated on the surface of a photothermal nanoparticle to actively capture and inactivate SARS-CoV-2. The photothermal nanoparticle is comprised of a semiconducting polymer core and a biocompatible polyethylene glycol surface decorated with neutralizing antibodies. Such nanoparticles displayed efficient capture of SARS-CoV-2 pseudoviruses, excellent photothermal effect, and complete inhibition of viral entry into ACE2-expressing host cells via simultaneous blocking and inactivating of the virus. This photothermal nanoparticle is a flexible platform that can be readily adapted to other SARS-CoV-2 antibodies and extended to novel therapeutic proteins, thus providing a broad range of protection against multiple strains of SARS-CoV-2.
Coronavirus disease 2019 (COVID-19), resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has spread worldwide and caused a global pandemic.\textsuperscript{1,2} As of October 12, 2020, SARS-CoV-2 has infected over 37 million people and caused more than one million deaths.\textsuperscript{3} The virus can induce severe symptoms such as acute respiratory distress syndrome, cytokine release syndrome, and cardiovascular damage, as well as increase mortality in patients.\textsuperscript{4-6} SARS-CoV-2 gains entry into cells through high affinity binding of the receptor binding domain of the spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface.\textsuperscript{7,8}

Vaccines in development to protect against SARS-CoV-2 infection have shown promising results in phase 1 and 2 clinical trials,\textsuperscript{9-13} however the process to vaccine approval and deployment may take months to years to realize. Moreover, it remains unclear whether vaccines will confer long-term protection, further complicating the path toward ending the pandemic.\textsuperscript{14} Currently, there are limited therapeutic regimens proven to clear the viral infection in all patients evaluated. Existing FDA-approved drugs have been applied to COVID-19 treatment and shown some success, but specific, effective therapies have been yet to be clinically approved.\textsuperscript{15-17} In an alternative approach, transfusion of convalescent plasma from recovered patients containing antibodies specific for SARS-CoV-2 into COVID-19 patients was shown to reduce viral load and may limit the severity or duration of illness in some patients due to the presence of pre-existing neutralizing antibodies.\textsuperscript{18} However, intravenous administration of convalescent plasma involves logistical hurdles, including availability of donor plasma and the need for a designated medical facility.\textsuperscript{19}

Antibody-dependent enhancement (ADE), caused by binding of non-neutralizing antibodies to SARS-CoV-2, remains a concern for antibody-based vaccines, therapies, and convalescent plasma because it can further aggravate a patient’s condition through enhancement of viral infection.\textsuperscript{20-23} High-affinity monoclonal neutralizing antibodies against SARS-CoV-2 may circumvent some of the potential risk of ADE, as they often display much higher affinities for SARS-CoV-2 spike protein (<1 nM)\textsuperscript{24-26} than those of ACE2 (~15–40 nM)\textsuperscript{27-30} and can be produced in mass scale. Recently, several monoclonal neutralizing antibodies cloned using B cells from COVID-19 patients have been shown to effectively block the interaction between SARS-CoV-2 spike protein and ACE2.\textsuperscript{31-35}
Several nanomaterial-based approaches have been investigated for virus detection, vaccine delivery, and viral capture, however, the lack of a method to effectively capture and inactivate the virus after binding—which may lead to ADE—remains to be addressed. Herein we report the development of a strategy utilizing photothermal nanoparticles decorated with high-affinity neutralizing antibodies in order to effectively capture and inactivate SARS-CoV-2 (Figure 1a). Each photothermal nanoparticle contains a semiconducting polymer core, poly[2,6-(4,4-bis-(2-ethylhexyl)-4H-cyclopenta[2,1-b;3,4-b’]dithiophene)-alt-4,7(2,1,3-benzothiadiazole)] (PCPDTBT), enabling generation of intensive local heat after being excited by suitable light sources. In addition, photothermal nanoparticles can achieve highly specific and noninvasive photothermal killing of biological targets such as virus, bacteria, and tumors without damaging the surrounding healthy tissues. An amphiphilic polymer shell, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000], is applied to encapsulate the PCPDTBT core. The nanoparticle surface is functionalized with a monoclonal neutralizing antibody specific to the SARS-CoV-2 spike protein which enables selective and efficient capturing of SARS-CoV-2 with high affinity (0.07 nM), thus preventing the entry of SARS-CoV-2 into host cells. Upon excitation by a 650-nm light-emitting diode (LED), which possesses a more desirable safety profile compared to conventional laser excitation, the photothermal nanoparticles directly inactivate the captured SARS-CoV-2 by heat. The unique design of our photothermal nanoparticles not only synergizes with the neutralizing function of the antibody in capturing SARS-CoV-2, but may also mitigate the potential risks of ADE through direct inactivation of the coronavirus via the photothermal effect.
Figure 1. Structure and characterization of photothermal nanoparticles. (a) Schematic illustration of the photothermal nanoparticle for virus capture and inactivation. Inset: a TEM image of the photothermal nanoparticles. Scale bar: 50 nm. (b) DLS size distribution of photothermal nanoparticles. (c) UV–vis absorption spectrum of photothermal nanoparticles. (d) Fluorescent images and fluorescence intensity profiles of the neutralizing antibody-conjugated photothermal nanoparticles labeled by DiR (red) and immunostaining by a secondary Alexa Fluor 488 anti-IgG2b antibody (green) and their overlaid images. Line scan was used to indicate the fluorescence profile and co-localization for single nanoparticles. Excitation: 488 nm (green channel) and 740 nm (red channel). Scale bars: 2.5 µm.

Photothermal nanoparticles were prepared by using 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000, NHS ester] (DSPE-PEG<sub>2000</sub>-NHS).
as the matrix to encapsulate PCPDTBTT through self-assembly.\textsuperscript{47} Subsequently, an anti-SARS-CoV-2 neutralizing antibody was crosslinked to the nanoparticles via reaction of NHS esters with amines on the antibody surface. Using dynamic light scattering (DLS), we determined the hydrodynamic diameters of the photothermal nanoparticles to be \( \sim 90 \) nm, which was validated by transmission electron microscopy (TEM) (Figure 1b). In addition, the photothermal nanoparticles exhibited good stability without forming any aggregation or precipitation after being stored in aqueous dispersions at 4 °C for several weeks (Figure S1). The ultraviolet to the visible light absorption spectrum of the photothermal nanoparticles covers a broad range from 500 to 850 nm in the red and near-infrared range, favoring their application as photothermal agents for light-triggered inactivating of the SARS-CoV-2 using infrared excitation (Figure 1c). Surface conjugation of the anti-SARS-CoV-2 neutralizing antibody (IgG2b) was further validated by fluorescent imaging analysis. Briefly, DiOC\textsubscript{18}(7) (DiR) lipophilic dye capable of emitting a fluorescent signal at \( \sim 780 \) nm was co-encapsulated in the photothermal nanoparticles (Figure 1d). After immunostaining with a secondary Alexa Fluor-488-labeled anti-IgG2b antibody, subsequent visualization by fluorescence microscopy indicated specific staining of the neutralizing antibody-conjugated photothermal nanoparticles, as demonstrated by good colocalization between the Alexa Fluor-488 signal and the DiR dye (Pearson's correlation coefficient \( \approx 0.9 \), calculated by ImageJ).

\textbf{Figure 2.} Photothermal characterization of the nanoparticles. (a) Temperature changes of the photothermal nanoparticles (200 µL) and 1× PBS (200 µL) after the excitation with a 650-nm LED at the indicated times. Error bars indicate ± SEM. n = 3 per group. (b) Schematic diagram (top) and electrical diagram (bottom) of voltage clamp microscope setup used to measure local temperature change. (c) A representative trace of temperature increase during 10 ms excitation with a 650-nm LED at 1.7 W/cm\textsuperscript{2} intensity.

Since the photothermal nanoparticles exhibited excellent absorption in the near-infrared region, we hypothesized that they could effectively generate local heating after light excitation with a suitable wavelength. To test this hypothesis, we applied a 650-nm LED with a power density of 250 mW/cm\textsuperscript{2} to excite the photothermal nanoparticles, because it would fit the absorption
spectrum of the nanoparticles and could be safely used to excite healthy cells and tissues.\textsuperscript{48, 49} The nanoparticles were dispersed in phosphate buffered saline (1 × PBS; pH 7.4) at a concentration of 100 µg/mL, then subjected to LED excitation. As expected, a time-dependent temperature increase from 20 °C to 50 °C was observed within 10 min after light exposure (Figure 2a). In contrast, less than 2 °C of temperature change was observed in PBS alone, indicating the effect was specific to the nanoparticles (Figure 2a). Since the temperature of the entire solution exceeded 50 °C, we rationalized that the local heating rate of the photothermal nanoparticles should be much higher, and would thus enable effective inactivation of SARS-CoV-2. To test this hypothesis, we further evaluated local temperature changes following excitation using an LED-coupled voltage-clamp setup (Figure 2b) to understand the transient photothermal response of the nanoparticles.\textsuperscript{50} The nanoparticles were drop-casted onto the glass coverslip and the aggregate was covered with a PBS solution. The glass micropipette electrode was placed in close proximity to the surface of the aggregated nanoparticles. Then, a 650-nm LED was used to deliver 10 ms light pulses and the current response through the pipette was measured (Figure S2). The analysis revealed a 0.7 °C increase in the local temperature after each light pulse (Figure 2c), which corresponds to an initial heating rate of 70 °C/s. After the end of the pulse, the temperature decayed with a \( \sim 28 \) ms time constant. While the local temperature change observed in the measurement is lower than observed previously for silicon nanostructures,\textsuperscript{51, 52} the light density used for excitation is more than 100-times lower due to application of LED rather than focused laser. Additionally, the longer decay time constant suggests higher thermal resistance at the organic nanoparticle-water interface compared to inorganic nanostructures.\textsuperscript{50} The measurements further suggest strong photothermal response produced by the nanoparticles, which we expected would inactivate the viral particles due to the intense local heating.
Next, we sought to determine if we could use the newly engineered photothermal nanoparticles to inhibit the infection of ACE2-expressing host cells by SARS-CoV-2. Due to the high risk of infection associated with live SARS-CoV-2, we decided to utilize alternative replication-incompetent viruses pseudotyped with the SARS-CoV-2 spike protein in order to evaluate efficacy of the nanoparticles. Pseudotyped viruses have been routinely employed to provide significantly safer conditions in which to study highly infectious viruses. As an initial proof-of-concept, we employed the vesicular stomatitis virus pseudotyped with the SARS-CoV-2 spike protein (SARS-CoV-2 VSV-GFP). The SARS-CoV-2 VSV-GFP pseudovirus enables transient expression of green fluorescent protein (GFP) upon entry into the host cell (Figure 3a), facilitating direct monitoring of viral uptake following incubation with the nanoparticles and photothermal treatment. In the absence of nanoparticles, HEK293T cells engineered to overexpress ACE2 (ACE2/HEK293T) were susceptible to pseudovirus infection as demonstrated by GFP expression.
after 24 h incubation (Figure 3b). A dose-dependent containment of the pseudovirus was observed upon addition of the antibody-conjugated photothermal nanoparticles (0.5 ~ 10 µg/mL) and 650-nm LED excitation (250 mW/cm², 10 min). Complete inhibition of pseudovirus infection was achieved at a concentration of 5 µg/mL with an IC₅₀ value of 1.68 µg/mL (Figure 3c, 3d and S3a), demonstrating the good virus inactivation efficiency of the nanoparticles. To confirm this effect was not dependent on the structure of the pseudovirus, we utilized a replication-incompetent lentivirus pseudotyped with SARS-CoV-2 spike protein (SARS-CoV-2 lentivirus-GFP), which stably integrates a gene encoding a GFP reporter into the host genome after infection (Figure 4a), for the subsequent in vitro viral infection study. As expected, in the absence of nanoparticles, the pseudovirus infected the ACE2/HEK293T cells, as indicated by GFP expression monitored at 48 h post infection (Figure 4b and S4a). After incubating with the neutralizing antibody-conjugated photothermal nanoparticles and applying 650-nm LED excitation (250 mW/cm², 10 min), infection by the SARS-CoV-2 lentivirus-GFP was inhibited in a dose-dependent fashion when the concentration of nanoparticles was increased from 0.5 µg/mL to 10 µg/mL, demonstrating complete inhibition of pseudovirus infection at a concentration of 5 µg/mL and an IC₅₀ of 0.23 µg/mL (Figure 4c, 4d, S3b, and S4b). Taken together, these data demonstrate the excellent inhibitory role of our antibody-photothermal nanoparticles in inactivating the SARS-CoV-2 pseudoviruses through the synergistic effect of the neutralizing antibody and photothermal treatment. Importantly, no toxicity was observed after treating the ACE2/HEK293T cells with different concentrations of the photothermal nanoparticles (Figure S5), providing further support for their safe use in biological systems.
Figure 4. SARS-CoV-2 lentivirus-GFP pseudovirus infection in ACE2/HEK293T cells. (a) Schematic illustration of SARS-CoV-2 lentivirus-GFP pseudovirus infecting ACE2/HEK293T cells. The spike protein on the pseudotyped virus surface binds to ACE2 (1), and infects the cell (2). The viral RNA is integrated into the host DNA (3) where it constitutively transcribes (4) and translates it (5) into GFP (6). (b) Fluorescent and BF-GFP merge images of ACE2/HEK293T cells before and after incubation with SARS-CoV-2 lentivirus-GFP. Scale bars: 100 µm. (c) Fluorescent and BF-GFP merge images of ACE2/HEK293T cells after incubation with SARS-CoV-2 lentivirus-GFP treated by different concentrations of the neutralizing antibody-conjugated photothermal nanoparticles and 650-nm LED excitation (250 mW/cm², 10 min). Scale bars: 100 µm. (d) SARS-CoV-2 lentivirus-GFP infectivity after incubation with different concentrations of the neutralizing antibody-conjugated photothermal nanoparticles and 650-nm LED excitation (250 mW/cm², 10 min). An IC₅₀ of 0.23 µg/mL was calculated from dose-response curve. Error bars indicate ± SEM. n = 6 per group.

CONCLUSION

In summary, we developed an antibody-conjugated photothermal nanoparticle for active capture and inactivation of SARS-CoV-2. The nanoparticles displayed excellent photothermal properties as demonstrated by generation of a significant amount of local heat upon LED light excitation in a short time. In the virus neutralization experiments, the antibody-conjugated photothermal nanoparticles together with LED excitation enabled successful capture and inactivation of two different types of SARS-CoV-2 pseudoviruses, which resulted in complete protection against viral infection in ACE2/HEK293T cells. The synergistic effect of antibody capture and photothermal treatment provides an excellent virus neutralization efficiency. This work demonstrates a proof-of-concept that photothermal inactivation could potentially serve as a preventative approach to inhibit ADE that arises due to incomplete neutralization of the SARS-CoV-2 during SARS-CoV-
2 infection and vaccination. Finally, our photothermal nanoparticle provides a flexible platform that can be readily adapted to target other strains of SARS-CoV-2 via conjugation to different antibodies or other novel therapeutic proteins and can be extended to other viruses, bacteria\(^{57}\) and malignant cells.\(^{58}\)

**MATERIALS AND METHODS**

**Preparation of Photothermal Nanoparticles**

PCPDTBT (0.2 mg) and DSPE-PEG\(_{2000}\)-NHS (2 mg) were dissolved and mixed in tetrahydrofuran (500 µL).\(^{47}\) For DiR labeled nanoparticles, 0.04 mg of DiR was further added into the mixture. The mixture was injected into 1 × PBS (10 mL) and sonicated using a probe sonicator (Qsonica Ultrasonic Homogenizer) on ice for 2 min. THF was then evaporated by rotary evaporator. The obtained nanoparticles were filtered through a 0.22 µm syringe filter and concentrated by ultrafiltration (Amicon® Ultra-15 Centrifugal Filter Unit with 100 KDa cutoff, 4000 × g, 4 °C, 5 min). Anti-SARS-CoV-2 neutralizing antibodies were added into the nanoparticle solution with a mass ratio of 1:10 (antibody: DSPE-PEG\(_{2000}\)-NHS) and stirred overnight at 4 °C to complete the conjugation.

**Nanoparticle Characterization**

The measurement of UV-vis absorption spectra was carried out using a UV-vis spectrophotometer (Thermo Scientific NanoDrop™ 2000). The sizes of the nanoparticles were measured by dynamic light scattering (DLS) particle size analyzer (Malvern Zetasizer). The sizes and morphologies of the nanoparticles were studied by transmission electron microscopy (TEM, JEM-2010F, JEOL, Japan).

**Fluorescent Imaging of Photothermal Nanoparticles**

The photothermal nanoparticles (100 µg/mL, 10 µL) was incubated with the secondary Alexa Fluor 488-labeled anti-IgG2b antibody (100 µg/mL, 10 µL) for 1 h. Single particle fluorescent images were captured by a fluorescence microscopy with a 100×/1.49 numerical aperture (NA) objective using a Nikon Ti-E inverted microscope. A 7-color solid state LED light source was connected with a liquid light guide to the microscope; the light then passes through a quad band-pass filter (ZET405-488-532-647m). The LED excitation wavelengths used were 470 ± 25 nm for
green channel and 740 ± 20 nm for red channel (Spectra X, Lumencor). The emissions from the nanoparticles and Alexa Fluor-488 were captured by an Andor iXon Ultra 888 back-illuminated electron multiplying CCD (EMCCD) camera (Oxford Instruments).

**Photothermal Test of Photothermal Nanoparticles**

Photothermal nanoparticles (100 µg/mL in 1 x PBS) were added into a well in a 96-well plate (flat bottom, GenClone®). A 650-nm LED (Spectra X, Lumencor) was applied to excite the nanoparticle solution for 10 min with a power density of 250 mW/cm². The temperature changes from 0 to 10 min were recorded by a probe thermometer. Each measurement was repeated three times. Temperature changes of pure 1 x PBS were also measured using the same method.

**Measurement of Transient Photothermal Response of Photothermal Nanoparticles**

Photothermal response measurements were performed on an upright microscope (Olympus, BX61WI) with a 20×/0.5 NA water-immersion objective. An LED light source (Lumencore Spectra X) with a 650 nm filter was used for excitation and was electronically controlled using transistor-transistor logic signals delivered from a digitizer (Molecular Devices, Digidata 1550). Voltage-clamp measurements were performed using Axopatch 200B amplifier (Molecular Devices). For the local temperature measurements, a pipette electrode (~0.8 MΩ at room temperature) filled with buffer solution (1 x PBS) was placed in a close proximity to the nanoparticles aggregated on top of glass coverslip submerged in PBS solution. Heat-induced currents were recorded in voltage-clamp mode. A laser pulse of 10 ms was delivered to the preparation 100 ms after the voltage jumped 0.5 mV below the holding potential. Current traces were recorded for the set of holding currents (Figure S2a) and the linear relationship between the holding current and photothermal current was established for different time points (Figure S2b). Temperature was inferred using a temperature-resistance calibration curve measured for the pipette.

**In Vitro Viral Infection of SARS-CoV-2 VSV-GFP Pseudovirus**

ACE2/HEK293T cells (5 × 10⁴ cells) were seeded into 96-well plates (flat bottom, GenClone®) and incubated overnight at 37 °C in a humidified CO₂ incubator. A dilution series of the photothermal nanoparticles was prepared in a final volume of 50 µL of Dulbecco’s Modified Eagle Medium (DMEM) for a single well. Simultaneously, 15 µL of SARS-CoV-2 VSV-GFP (2 × 10⁵ titering units (TU)/mL) was diluted into DMEM to a final volume of 50 µL for a single well. The
photothermal nanoparticles and SARS-CoV-2 VSV-GFP were combined to a total volume of 100 µL and incubated at 37°C for 1 h. After the initial incubation, the mixtures were excited by the 650-nm LED for 10 min with a power density of 250 mW/cm² and added to cells. After 2 h incubation, 100 µL of fresh cell culture media were further added into each well. Each group contains three wells for the subsequent imaging and quantification. After 24 h incubation, the cells were imaged with Leica fluorescence microscope using 10×/0.30 NA objective. The LED excitation wavelengths were 470 ± 25 nm for GFP (Spectra X, Lumencor). The emissions were captured by an Andor iXon Ultra 888 back-illuminated EMCCD camera (Oxford Instruments). GFP-positive cells were counted manually three times by objective and the viral infection rates were calculated as the ratio of GFP-positive cells in the group incubated with the nanoparticles and virus to that of the group incubated with virus alone.

In Vitro Viral Infection of SARS-CoV-2 Lentivirus-GFP Pseudovirus

ACE2/HEK293T cells (2 × 10⁴ cells) were seeded into 96-well plates (flat bottom, GenClone®) and incubated overnight at 37 °C in a humified CO₂ incubator. A serial dilution of the photothermal nanoparticles was prepared in a final volume of 50 µL of cell culture media for a single well. Simultaneously, 10 µL of SARS-CoV-2 lentivirus-GFP (1 × 10⁶ TU/mL) was diluted into cell culture media to a final volume of 50 µL for a single well. The photothermal nanoparticles and SARS-CoV-2 lentivirus-GFP were combined to a total volume of 100 µL and incubated at 37°C for 1 h. After the initial incubation, the mixtures were excited by the 650-nm LED for 10 min with a power density of 250 mW/cm² and added to cells. After 48 h incubation, cells were washed with 1 × PBS and fixed in 4% [w/v] paraformaldehyde for 15 min. Cells were then washed with 1 × PBS and further stained with Hoechst 33342 nuclear stain (2 µg/mL) for 15 min. The GFP expression monitored with a Nikon Ti-E inverted microscope using a 10×/0.30 NA objective. The LED excitation wavelengths were 395 ± 25 nm for Hoechst 33342 and 470 ± 25 nm for GFP (Spectra X, Lumencor). The emissions were captured by an Andor iXon Ultra 888 back-illuminated EMCCD camera (Oxford Instruments). The numbers of total cells and infected cells were counted in ImageJ using the following workflow: Adjust → Threshold (Otsu), Process → Binary → Fill Holes → Watershed, Analyze → Analyze Particles. GFP expression was first normalized to total number of cells as calculated by DAPI staining. Then, viral infection rates were calculated as the ratio of normalized GFP positive cells in the group incubated with the virus and nanoparticles to that of the group incubated with virus only.
ACKNOWLEDGMENTS

We thank Dr. Jeffrey Hubbell and his lab members for providing equipment for the nanoparticle synthesis. This work was supported by NIH New Innovator award 1DP2AI144245 (J.H.), NSF Career award 1653782 (J. H.) and NIDDK RC2DK122394 (E. C.). N.A. is supported by NIH T32DK007074 and J.R. is supported by the NSF Graduate Research Fellowships Program DGE-1746045.

AUTHOR INFORMATION

Author Contributions

X. C. and J. H. conceived the ideas and designed the project. J. H. supervised the project. X. C. synthesized, characterized the nanoparticles and conducted the in vitro viral infection experiments. A. P. measured the transient photothermal response and analyzed the data. Y. L. and J. S. performed the electron microscopy experiment and analyzed the data. N. A. and J. R. contributed to the imaging data analysis. M. C. maintained and provided the ACE2/HEK293T cells and advised on the in vitro SARS-CoV-2 VSV-GFP infection experiments. P. P.-M. produced the SARS-CoV-2 VSV-GFP pseudovirus and advised on the in vitro SARS-CoV-2 VSV-GFP infection experiments. X. C. and J. H. drafted the manuscript with input from A. P., N. A., J. R., E. C., and B. T.. E. C. and J. H. contributed to the funding acquisition.

Notes

The authors declare no competing interests.

REFERENCES


